Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glenmark Of India Plans U.S. Acquisition To Market Specialty Drugs

This article was originally published in PharmAsia News

Executive Summary

India's Glenmark Pharmaceuticals plans to acquire a U.S. company in a move to enter the U.S. market for its specialty drugs business. Currently, Glenmark specialty products are marketed in all markets except the United States and Japan. Glenmark CEO Glenn Saldanha would not comment on the size or timing of an acquisition, but confirmed the company does want to market its specialty products in regulated markets, particularly the United States. That product line is expected to be worth $35 million to the firm in the next fiscal period. (Click here for more

You may also be interested in...



PharmAsia News India Pharma Roundup: Glenmark, FMRAI, Synchron/Parexel, Suven Life Sciences, Merck/Ranbaxy/Teva/Credit Suisse

NEW DELHI - Mumbai-based Glenmark Pharmaceuticals has split its corporate structure into speciality and generic units to better manage the "diverse businesses that had both attained a critical mass.

Genomma Enjoys Strong Q2 Thanks To Big Gains in US

Mexico's Genomma Lab recorded strong double-digit growth for its OTC business in the second quarter as sales more than doubled at its US consumer health operation. 

Executives On The Move: New CEOs At Alentis Therapeutics, Melinta Therapeutics And NBE-Therapeutics

New board directors named at Autolus Therapeutics, Beximco Pharmaceuticals, Tetraphase Pharmaceuticals and Vesigen.

UsernamePublicRestriction

Register

MT125590

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel